An aminobisphosphonate and antimalarial agent
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Risedronate (sodium salt)

Item No. 20740

Technical Information
Formal Name
P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid, monosodium salt
CAS Number
115436-72-1
Molecular Formula
C7H10NO7P2 • Na
Formula Weight
Purity
≥95%
A crystalline solid
PBS (pH 7.2): 10 mg/ml
λmax
262 nm
SMILES
OC(P(O)(O)=O)(P(O)([O-])=O)CC1=CC=CN=C1.[Na+]
InChi Code
InChI=1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
InChi Key
DRFDPXKCEWYIAW-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Risedronate is a heterocyclic orally active aminobisphosphonate.1 Like other bisphosphonates, it inhibits bone resorption.2,1 In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo (25 mg/kg for one week).3 It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.4,2,1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Nuti, R. Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. Clin. Cases Miner. Bone Metab. 11(3), 208-214 (2014).

    2. Lems, W.F., and den Heijer, M. Established and forthcoming drugs for the treatment of osteoporosis. Neth. J. Med. 71(4), 188-193 (2013).

    3. Jordao, F.M., Saito, A.Y., Miguel, D.C., et alIn vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob. Agents Chemother. 55(5), 2026-2031 (2011).

    4. Pereira, R.M.R., de Carvalho, J.F., Paula, A.P., et alGuidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev. Bras. Reumatol. 52(4), 580-593 (2012).